anonymous
Guest
anonymous
Guest
Who is the main competition for Synthes CMF? I know in some markets CMF has gone to the trauma reps, but in others there are still solo CMF reps. Is there a good future with Synthes CMF?
This was once a great division. JnJ integrated the company under trauma and it went from a dominating market share lead to just being passed by KLS and now they are in third and continue to fall. Their compensation is the lowest in the industry. Pipeline is horrible. Their biggest issue is that even though they have CMF management again, over half of their acts are still being covered by trauma reps and that won’t change due CMF sales are needed to help keep them selling trauma in the smaller territories. The entire company is being run by guy who sold in cmf for just a couple of years. He’s a tool. JnJ will change this division once again in about two years and it will continue to decline. It’s very sad
If the territory is pretty much secured by Synthes CMF with very little competition, what are the thoughts? The area I am exploring would have trauma and cmf separate from each other. The trauma side has its own team and doesn’t cover any cmf.
the problem is why would you want to go to cmf to begin with? I was with this division for over 5 years, made some decent money, but ultimately this is junior varsity when it comes to titanium sales. The cmf call points are a pain in the ass long term, and with Stryker and KLS breathing down our back for these cases the pricing started to tumble...now go do more cases and make less money. Bailed to get into a neuro focused company doing some truly cool things. There are better jobs out there no doubt, but I guess its okay if you want to get into device sales? Although now I would caution people away from med device entirely, its not as lucrative or glamorous as it was long ago.
I’ve been with CMF for a very long time. It is so depressing to see such an amazing division be torn apart by senior leadership. Alex H. is in way over his head. Most of the reps don’t respect him and I don’t think anyone trusts Ken C. While I think dropping the hybrid model is a move in the right direction, it’s too little too late. Our pipeline is basically dry. Our competitors are passing us up. Most third party analysts say Stryker is the market leader in the US followed by KLS! No one would have imagined the day we would lose our dominating lead in this market but when you lose the majority of your good reps, market will be lost. I’m just trying to hold on for a few more years to hit the sweet spot for my pension. I think CMF is going to see another mass loss of our strongest reps in the next 5 years. So sad.
Some of those CMF managers have never sold a day in their life. That's a big kick in the ass to all of the hard working CMF reps who have been in the war zone for years.Synthes is trying to undue all the damage that JJG caused the last 4-5 years. They just hired ten or so dedicated CMF managers. None of them have significant management experience and most were below ave sales reps if they were ever in sales. Knowing the history of JnJ, this new experiment will last two years and they will then try something else for this division. The biggest short term issue is that they still don’t have any significant new products coming and contracting is way inferior to companies like Stryker. They are trying to hire back all the reps they have lost during this period but most of the goos ones won’t give them the time of day.